Materias dentro de su búsqueda.
Mostrando 1,821 - 1,840 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.45s Limitar resultados
  1. 1821
    Publicado 1850
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Congratulatory Address to Samuel Gaskell, Esq.: And One of Her Majesty's Commissioners in Lunacy, Etc. Etc.
  2. 1822
    “…AIM: To investigated the relationships between HER2, c-Jun N-terminal kinase (JNK) and protein kinase B (AKT) with respect to metastatic potential of HER2-positive gastric cancer (GC) cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-induced metastasis is mediated by AKT/JNK/EMT signaling pathway in gastric cancer
  3. 1823
    “…Circulating tumor cells (CTCs) in women with advanced estrogen receptor-positive/HER2-negative breast cancer acquire a HER2-positive subpopulation following multiple courses of therapy(1,2). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 expression identifies dynamic functional states within circulating breast cancer cells
  4. 1824
    por Clarke, James
    Publicado 1885
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Piece of Stick Introduced by a Woman into the Interior of Her Uterus for the Cure of Amenorrhœa: Removal
  5. 1825
    “…BACKGROUND: Neuregulins (NRG) are a family of epidermal growth factor ligands which act through binding to HER3 and HER4 receptors. NRGs are widely expressed in solid tumors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies
  6. 1826
    “…We constructed breast cancer cell lines differing in HER2 expression by transducing HER2 cDNA or short hairpin RNA against HER2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo
  7. 1827
    Publicado 1918
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Four Ceremonies: The Cavell Statue, Her Memorial, King Edward VII. Ward, and the Bishop's Palace
  8. 1828
    “…Our work is focused on better understanding the safety and efficacy determinants of IgG antibody preparations when used during pregnancy to benefit the mother and her baby. Using pregnant guinea pigs, we demonstrated that biodistribution of administered IgG to the fetus increases with gestation and results in lower maternal and higher fetal antibody concentrations as pregnancy progresses. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Passive Immunoprophylaxis for the Protection of the Mother and Her Baby: Insights from In Vivo Models of Antibody Transport
  9. 1829
    “…Several investigators have suggested the possibility that the expression of both EGFR and HER2 could be utilized for molecularly targeted therapy in urinary bladder cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in Urothelial Carcinomas
  10. 1830
    “…In vitro studies showed specific uptake of Z(HER2)-ΔHBc particles in HER2 expressing cancer cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo
  11. 1831
    “…Around, 30–40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
  12. 1832
    “…She was treated with aggressive HER2-directed chemotherapy and hepatic metastasectomy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Liver resection for HER2-enriched breast cancer metastasis: case report and review of the literature
  13. 1833
    “…Moreover, although CXCR4 inhibitors significantly reduce myofibroblast content in all BC subtypes, they decrease angiogenesis only in HER2 BC. Thus, our findings suggest that targeting CXCR4 could provide some therapeutic interest for HER2 BC patients, whereas it has no impact or could even be detrimental for TN BC patients.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
  14. 1834
    “…Treatment with targeted therapeutics such as the EGFR-targeting antibody cetuximab or the HER2-targeting antibody trastuzumab is either ineffective or moderately effective in this disease, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines
  15. 1835
    “…HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
  16. 1836
    “…Our results demonstrate that resveratrol, acting as a proteasome inhibitor, leads to Δ16HER2 accumulation which favors the formation of Δ16HER2/HER3 heterodimers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor
  17. 1837
    “…BACKGROUND: A wide range of response rates have been reported in HER2-positive gastric cancer (GC) patients treated with trastuzumab. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
  18. 1838
    “…Complete genome sequences were obtained for Zika viruses isolated from the breast milk of a Venezuelan patient and her child, who was exclusively breastfeeding at the time. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Complete Genome Sequences of Identical Zika virus Isolates in a Nursing Mother and Her Infant
  19. 1839
    “…Trastuzumab is regarded as the primary therapy for patients with HER2-enriched breast cancer, but the pathological complete response for advanced cases is less than 30%. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient
  20. 1840
    por Nami, Babak, Wang, Zhixiang
    Publicado 2017
    “…Trastuzumab is approved by FDA to specifically target HER2 for treating HER2+ BC. However, about 60% of patients with HER2+ breast tumor develop de novo resistance to trastuzumab, partially due to the loss of expression of HER2 extracellular domain on their tumor cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
Herramientas de búsqueda: RSS